by Laura Turbay | Nov 13, 2024
The race to supply weight-loss drugs to nearly half of Americans that classify as obese, is on. Eli Lilly’s stock boomed after they released their blockbuster weight loss drug Zepbound last year, consecrating the Indiana-based drugmaker as one of the top...
by Cailley LaPara | Sep 20, 2022
The economy may be ailing but dominant healthcare stocks have so far resisted infection, and look poised to continue thriving. Pharmacy retailer and insurer CVS (CVS) closed Friday at $102 per share, just about where it began the year. Leading drug manufacturer Eli...
by Lucy Papachristou | Sep 20, 2022
By Lucy Papachristou Federal legislative overhaul of the healthcare sector is throwing a wrench into Big Pharma’s growth this fall, but companies are expected to weather the storm in a market hungry for new drug therapies. Stocks of insulin producers Eli...
